Matakidou A, El Galta R, Rudd M F, Webb E L, Bridle H, Eisen T, Houlston R S
Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK.
Br J Cancer. 2007 Jun 18;96(12):1904-7. doi: 10.1038/sj.bjc.6603816. Epub 2007 May 22.
The Gly388Arg polymorphism in the fibroblast growth factor receptor 4 (FGFR4) gene has been reported to influence prognosis in a wide variety of cancer types. To determine whether Gly388Arg is a marker for lung cancer prognosis, we genotyped 619 lung cancer patients with incident disease and examined the relationship between genotype and overall survival. While we employed a comprehensive set of statistical tests, including those sensitive to the detection of differences in early survival, our data provide little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis.
据报道，成纤维细胞生长因子受体4（FGFR4）基因中的Gly388Arg多态性会影响多种癌症类型的预后。为了确定Gly388Arg是否为肺癌预后的标志物，我们对619例新发肺癌患者进行了基因分型，并研究了基因型与总生存期之间的关系。尽管我们采用了一系列全面的统计测试，包括那些对早期生存差异检测敏感的测试，但我们的数据几乎没有证据支持FGFR4 Gly388Arg多态性是肺癌预后的临床有用标志物这一观点。
